Roche’s Actemra needs a REMS
Executive Summary
FDA announced Dec. 4 that a Risk Evaluation and Mitigation Strategy will be required of Roche's Actemra (tocilizumab), possibly pushing its launch back to 2010, and sending a message to other companies that any drug proposed with a comprehensive safety plan will most likely require a REMS. Roche had proposed an extensive post-marketing plan to monitor safety for the novel rheumatoid arthritis drug, which paved the way for a positive advisory committee review (1"The Pink Sheet," Aug. 4, 2008, p. 11). Additional non-clinical studies are also required. Roche expects to re-submit Actemra, which received a "complete response" letter in September, in the third quarter of 2009
You may also be interested in...
Roche’s Actemra Postmarket Safety Plan May Obviate Need For REMS
Roche may have staved off the imposition of a REMS for its rheumatoid arthritis candidate Actemra by proposing a robust pharmacovigilance of its own
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.
ASCO - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO
Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma, but increases in liver enzymes including two cases of Hy’s law have cast some shade over the INDIGO data.